Connect with us

Cannabis News

Ohio House Passes Bill To Remove Voter-Approved Marijuana Legalization Protections And Restrict Hemp Market

Published

on

The Ohio House of Representatives has passed a bill that would do just that make significant changes to the state’s voter-approved marijuana legalization law removing several protections for consumers, while also adding some new restrictions on hemp products intended to align the two sectors of the cannabis industry.

After passing through several House committees this week, with major amendments, the House approved Sen. Stephen Huffman’s (R) legislation on a vote of 87-8 on Wednesday.

Although the measure was previously approved by the Senate, it will have to return to that chamber for concurrence, or go to a bicameral conference committee, before going to the governor’s desk.

The House watered down some controversial provisions of the Senate-passed bill, but advocates are concerned that it would still make major changes to the marijuana law voters approve in 2023.

Rep. Brian Stewart (R), who has led the legislation through the House, argued before the vote that the legislation effectively achieves “carefully crafted compromise” among lawmakers with differing views on cannabis issues.

“It’s been very difficult to debate this bill, but most of our important bills usually are. Instead of being some kind of weak-sauce tie-breaker mash-up, this bill does what we claim we want to come to Columbus,” he said. “It tackles the issue head-on. It makes tough decisions. It respects and implements the views of residents and advocates from affected industries. This bill strikes a good balance between Ohioans’ individual liberties, their safety, the financial well-being of our local communities, and the need to protect the health and safety of Ohio’s children.”

Rep. Jamie Callender (R), who sponsored legislation to legalize marijuana before voters passed the reform on the ballot, said the bill is “not perfect,” but argued that lawmakers “must take action” to address intoxicating hemp and other pending issues.

“This is the revised code we’re writing,” he said. “I anticipate that there will be many more bills on these issues in the near and long term, as there should be … I will continue to work with all of them to make it better.”

While its supporters have described it as a less hands-off approach than the original Senate bill, the measure would make significant changes to existing legalization law, with several provisions that advocates say are in direct conflict with the will of voters and represent legislative overreach.

For example, the proposal would eliminate language in the current statute that provides anti-discrimination protections for people who legally use cannabis. It includes safeguards against adverse action in the context of child custody rights, the ability to perform organ transplants, and professional licensing.

It would also recriminalize possession of marijuana from any source other than a state-licensed Ohio dispensary or possession of marijuana from a legal household. Because of this, people can be charged with a felony for carrying cannabis purchased from a legal Michigan store in the Michigan area.

It would also ban the smoking of cannabis in outdoor public places, such as bar patios, and ban landlords from vaping marijuana in rental properties. Violation of this latter policy, even if it involves vaping in a person’s backyard in a rental property, would be a misdemeanor offense.

Karen O’Keefe, director of state policy for the Marijuana Policy Project (MPP), said in a letter to House lawmakers on Wednesday that SB 56 today “eliminates key protections of the law enacted by voters and re-criminalizes harmless behaviors that voters legalized.”

“Please reject this erosion of the liberties established by the voters,” he said.

Unlike the Senate-passed version of the bill, the House alternative would send cannabis sales tax revenue to local governments.

The legislation, amended by the House Judiciary Committee on Tuesday, also adds new restrictions on the hemp market. With the exception of beverages, hemp products would only be allowed to be sold in licensed hemp dispensaries.

Stores and breweries would be allowed to sell hemp-derived THC drinks, with new advertising restrictions to avoid appealing to youth. Products for on-premise consumption would be limited to 5 mg of THC, but adults could buy drinks of up to 10 mg to take home. Stronger drinks could also be manufactured in Ohio, but only for sale to people outside the state.

The bill would also include a new $1.20 per liter tax on hemp beverages.

The measure Earlier on Wednesday, the Treasury Board also amended it to clarify that people seeking to have their marijuana possession charges dropped would not have to prove the exact amount of cannabis they possessed. The amendment would also allow for dismissal of dismissed marijuana charges, not just convictions.

The amendment also aligns the beverage cannabinoid policy with the beverage laws and clarifies that the penalties for selling marijuana, hemp beverages or cannabinoid products to a minor would be the same regardless of the type of product.

Wednesday’s House vote comes weeks after the governor issued emergency regulations banning the sale of hemp products for 90 dayswith instructions to the legislature to consider permanent regulations. Last week, however, a county judge ordered the state to enforce that policy in response to a legal challenge.

“Quite frankly, the legislature didn’t take action,” Gov. Mike DeWine (R) said in an interview published this week. “I’m still hopeful that the legislature will step in and take action.”

House Speaker Matt Huffman (R) recently commented on the relative lack of progress on marijuana and hemp legislation since voters approved legalization on the ballot in 2023, highlighting the stark divisions within the Republican caucus.

There are “people who think marijuana should be legalized and regulated,” others who “think hemp products should be on par with everything that happened in the statute that started and then “people, like me, who are prohibitionists, don’t think it should be legalized at all and should be rare,” he said.

“I would say the prohibitionists have lost this debate.”


It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.


Learn more about our marijuana bill tracking and become a Patreon supporter to gain access

Meanwhile, last month, the Ohio Department of Cannabis Control (DCC) introduced new proposed rules to underpin the state’s marijuana legalization law. establishing plans to update regulations on labeling and packaging requirements.

The proposal arrived a few weeks later Medical and adult marijuana sales in Ohio officially surpassed $3 billionData from the state Department of Commerce (DOC) shows.

the state About $703 million worth of recreational cannabis was sold in the first year the law was enactedAccording to data from DCC.

In March, a survey of 38 municipalities by the Ohio State University (OSU) Moritz School of Law found local leaders were “unequivocally opposed” to earlier proposals which would have cut planned funding..

Meanwhile, in Ohio, adults can buy more than double the amount of marijuana starting in June than were under previous limits, state officials determined that the market could sustainably supply patients and adult users of medical cannabis.

The governor announced his desire individually in March Marijuana tax revenue to support police training, local jails and behavioral health services. He said funding for police training was a top priority, even if it wasn’t approved by voters in 2023.

Ohio’s Senate President also pushed back against criticism of the Senate bill, claiming that the legislation does not respect the will of the electorate and it would have little effect on the products available in stores.

user photo Philip Steffan.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Cannabis News

Tilray Medical announces commercial launch of medical cannabis in Panama

Published

on

By

Tilray Medical has announced the launch of its first medical cannabis product in Panama, part of the company’s continued global expansion and commitment to improving patient access to pharmaceutical grade cannabinoids worldwide.

Following the successful shipment of Tilray Oral Solution CBD100 from Tilray Medical’s EU-GMP certified production facilities in Portugal through a joint venture with Solana Life Group S. de RL, the Product is to be distributed through Farmacias Arrocha, one of the leading pharmaceutical chains in Panama, where patients will be able to access Tilray Oral Solution CBD with medical prescription100. This is expected to provide patients and healthcare professionals with access to regulated medical cannabis of pharmaceutical quality through established healthcare channels.

Rajnish Ohri, International President, Tilray Brands, said: “At Tilray Medical, we believe that every patient deserves access to safe, consistent, pharmaceutical-grade cannabis products. The launch in Panama reflects our broader vision to expand access to cannabinoid-based medicines around the world. We want pharmacists and patients to help shape the future of responsible access, advance medical education and provide high-quality treatment options that improve lives.”

The launch supports the Panamanian medical cannabis framework established by Law 242 of 2021 and follows important regulatory advances made by the Ministry of Health, including No. 0406 of May 12, 2026. The decision, which established the main conditions for the admission of patients. The Ministry also recently introduced the System for the Identification of Medical Cannabis Users and Authorized Caregivers (SIUCMAA), creating a structured way to authorize medical practitioners and register patients.

Manufactured in Portugal under strict European Union Good Manufacturing Practice (EU-GMP) standards, Tilray Oral Solution CBD100 is intended for use in patients with qualified medical conditions permitted under Panamanian law, where permitted. The products reflect Tilray Medical’s longstanding commitment to pharmaceutical quality, product consistency, patient safety and regulatory compliance.

Tilray Medical’s advanced cultivation and manufacturing facilities in Portugal serve as a strategic global export hub, supplying EU-GMP certified medical cannabis products to regulated markets worldwide. The platform enables Tilray Medical to effectively support growing international demand while maintaining the highest pharmaceutical manufacturing standards across its global operations.

For more information:
Tilray
www.tilray.com

Continue Reading

Cannabis News

Medical Marijuana Is ‘Effective’ In Providing Relief To Patients With Restless Legs Syndrome, Study Shows

Published

on

By

People with restless leg syndrome (RLS) may find “significant” long-term relief with cannabis treatment, according to a new study.

While dopamine agonists have traditionally been the “first-line treatment” for RLS, recent studies indicate that gabapentinoids are now being recommended, the researchers said. Because cannabinoids, like gabapentinoids, inhibit a certain type of amino acid associated with the disorder, scientists decided to test their therapeutic effectiveness.

The open-label exploratory study, conducted by European researchers at the University of Madrid and published in the Journal of Neurology, found that a cannabis product containing 2.7 mg of THC and 2.5 mg of CBD was “effective in reducing RLS severity” among patients with multiple sclerosis and “associated idiopathic RLS.”

“Improvements were observed after 1 to 3 months of treatment and were maintained after 1 year among patients who continued therapy,” the study of 18 patients with RLS showed. For those who remained in treatment after a year, 67 percent “continued to show sustained improvement.”

The the findings it may not be surprising that cannabis in particular is known to reduce the severity of muscle spasms and related conditions, but its effectiveness for RLS is remarkable given that no state specifically lists it as a condition for medical cannabis.

Of course, RLS can be a symptom of other general disorders like multiple sclerosis, and some states give doctors more latitude to make recommendations for medical marijuana for any condition they see fit.

In any case, research outside of Spain could be based on research into alternative treatment options that could replace dopamine agonists in the treatment of restless legs syndrome.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Wyoming AG keeps cannabis on Schedule I, rejects federal reclassification

Published

on

By











Wyoming Attorney General Keith Kautz announced on July 7 that he would keep all marijuana products in Schedule I of Wyoming’s Controlled Substances Act, refusing to align the state’s cannabis policy with the federal reorganization order issued earlier this year.

Kautz, who also serves as Wyoming’s drug and substance abuse commissioner, held a public hearing on June 18 after filing an objection to aligning the state’s cannabis schedule with a federal amendment on May 27. State law requires the commissioner to give interested parties an opportunity to be heard after that objection, but only nine people responded. Four email comments supported leaving cannabis as a Schedule I drug, four as Schedule III. It was approved for use and one person attended the hearing to request that cannabis remain in Schedule I.

His decision follows an April 2026 order signed by U.S. Attorney General Todd Blanche that bans state-licensed medical cannabis, FDA-approved cannabis products, cannabis extracts and naturally derived delta-9 THC III.

Kautz’s office says: “After consideration of all stakeholder comments, the commissioner has determined that all marijuana products, including marijuana subject to the state’s medical marijuana license, will remain in Schedule I of the Wyoming Controlled Substances Act.”

His announcement adds, “The decision to reschedule medical marijuana and marijuana products is an important policy decision that is best left to the Wyoming Legislature and should not be made through administrative rule.”

Wyoming remains one of eight states without a medical cannabis program. A December 2020 poll by the University of Wyoming’s Wyoming Center for Polling and Analysis found that 85 percent of state residents support legalizing medical cannabis, despite a failed 2024 ballot initiative effort. Possession of three ounces or less carries up to 12 months in prison under current state law, and selling any amount is punishable by up to 10 years in prison and a $10,000 fine.

Kautz says his office will “properly schedule products approved by the United States Food and Drug Administration once that agency has approved the product,” pointing to the Schedules II and III listings of Cesamet and Dronabinol as evidence that the state complies with federal cannabinoid drug law.










Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media